EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Simultaneous Activation of Beta‐Oxidation and De Novo Lipogenesis in MASLD ‐ HCC : A New Paradigm

Fatima Dahboul, Jihan Sun, Benjamin Buchard, Natali Abeywickrama-Samarakoon, Estelle Pujos-Guillot, Stéphanie Durand, Mélanie Petera, Delphine Centeno, Francesca Guerrieri, Massimiliano Cocca iD, Massimo Levrero iD, Adrien Rossary und 4 weitere

Liver International · 2025

DOI: 10.1111/liv.70006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, 2025. Verfasst von Fatima Dahboul und 15 weiteren Autor:innen. Beteiligte Einrichtung: Human Nutrition Unit 1019, INRAE, Clermont Auvergne University, Clermont-Ferrand, France. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Lipogenesis, Liver Neoplasms, Fatty Liver. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Société Nationale Française de Gastro-Entérologie, Emergence de Jeune Equipe INRA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Metabolic dysfunction‐associated steatotic liver disease (MASLD) is the most common cause of hepatocellular carcinoma (HCC). In this study, we combine metabolomic and gene expression analysis to compare HCC tissues with non‐tumoural tissues (NTT).

Methods

A non‐targeted metabolomic strategy LC–MS was applied to 52 pairs of human MASLD‐HCC and NTT separated into 2 groups according to fibrosis severity F0F1‐F2 versus F3F4. The expression of genes related to de Novo lipogenesis (DNL) and fatty acid oxidation (FAO) has been analysed by quantitative RT‐PCR and/or interrogation of RNA‐seq datasets in 259 pairs of tissues (MASLD‐HCC vs. VIRUS‐HCC).

Results

Metabolomic analysis revealed that acylcarnitines were the main discriminating metabolites according to fibrosis severity when we compared MASLD‐HCC‐F0F1‐F2 versus NTT and MASLD‐HCC‐F3F4 versus NTT. Based on these metabolomic data, the analysis of a panel of 15 selected genes related to DNL and FAO indicated that there is no difference between the 2 groups of MASLD‐HCC. In contrast the same comparative gene analysis according to the aetiology of HCC: MASLD‐HCC versus VIRUS‐HCC showed that both aetiologies shared the same upregulation of genes involved in DNL. However, five genes involved in FAO (HADHA, CRAT, CPT1, CPT2 and PPARA) are upregulated exclusively in MASLD‐HCC. This result indicates that FAO and DNL pathways are simultaneously activated in MASLD‐HCC in contrast to VIRUS‐HCC.

Conclusions

These results suggest that, the involvement of adaptive metabolic pathways is different depending on the aetiology of HCC. Moreover, the dogma that simultaneous activation of FAO and DNL is incompatible in cancer would not apply to MASLD‐HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLipogenesisLiver NeoplasmsFatty LiverHumansOxidation-ReductionMaleFemaleMiddle AgedMetabolomicsCarnitineLiverFatty Acids

Stichwörter der Autor:innen

MASLD‐HCCVIRUS‐HCCde novo lipogenesisfatty acid oxidationhepatocellular carcinomamass spectrometry analysis and quantitative real‐time PCR

Substanzen

CarnitineacylcarnitineFatty Acids

Autor:innen und Institutionen

  • Human Nutrition Unit 1019, INRAE, Clermont Auvergne University, Clermont-Ferrand, France.
  • EFS, INSERM, UMR RIGHT, Franche-Comté University, Besançon, France.
  • Department of Digestive and Hepatobiliary Medicine, CHU Clermont-Ferrand, Clermont-Ferrand, France.
  • Human Nutrition Unit 1019, Plate-Forme d'Exploration du Métabolisme, MetaboHUB-Clermont, INRAE, Clermont Auvergne University, Clermont-Ferrand, France.
  • INSERM U1052, CNRS UMR 5286, Cancer Research Center of Lyon (CRCL), Lyon, France.
  • Institute of Hepatology Lyon (IHL), Lyon, France.

ORCID-Profile: Massimiliano Cocca, Massimo Levrero, Delphine Weil, Vincent Di Martino, Aicha Demidem

Förderung

  • Société Nationale Française de Gastro-Entérologie
  • Emergence de Jeune Equipe INRA

Zitieren

APA

Dahboul, F., Sun, J., Buchard, B., Abeywickrama-Samarakoon, N., Pujos-Guillot, E., Durand, S., Petera, M., Centeno, D., Guerrieri, F., Cocca, M., Levrero, M., Rossary, A., Weil, D., Di Martino, V., Demidem, A., & Abergel, A. (2025). Simultaneous Activation of Beta‐Oxidation and De Novo Lipogenesis in MASLD ‐ HCC : A New Paradigm. Liver International. https://doi.org/10.1111/liv.70006

Vancouver

Dahboul F, Sun J, Buchard B, Abeywickrama-Samarakoon N, Pujos-Guillot E, Durand S, et al. Simultaneous Activation of Beta‐Oxidation and De Novo Lipogenesis in MASLD ‐ HCC : A New Paradigm. Liver International. 2025. doi:10.1111/liv.70006

BibTeX
@article{Dahboul2025,
  author = {Dahboul, Fatima and Sun, Jihan and Buchard, Benjamin and Abeywickrama-Samarakoon, Natali and Pujos-Guillot, Estelle and Durand, Stéphanie and Petera, Mélanie and Centeno, Delphine and Guerrieri, Francesca and Cocca, Massimiliano and Levrero, Massimo and Rossary, Adrien and Weil, Delphine and Di Martino, Vincent and Demidem, Aicha and Abergel, Armando},
  title = {Simultaneous Activation of Beta‐Oxidation and De Novo Lipogenesis in MASLD ‐ HCC : A New Paradigm},
  journal = {Liver International},
  year = {2025},
  doi = {10.1111/liv.70006}
}
Kostenlos starten →